Welcome to the MDS 2021 Interactive Programme
The congress will officially run on Eastern Daylight Time Zone EDT (Toronto time zone, UTC-4)
To convert the meeting times to your local time Click Here
Please note that all sessions will run at their scheduled time and be followed by a LIVE Q&A at the end
The viewing of sessions cannot be accessed from this congress calendar. All sessions are accessible via the Virtual Platform
Session Description:
David Roth, MD is the Chief Medical Officer of Syros Pharmaceuticals and will present an overview of company’s research in hematologic malignancies with a special focus on tamibarotene (formerly SY-1425), an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, that is currently being developed in genomically defined subsets of patients whose disease is characterized by the overexpression of the RARA gene. Dr. Roth will present the data that supported the company’s current clinical focus including the phase 3 SELECT-MDS-1 study of tamibarotene in combination with azacitidine in RARA-positive newly diagnosed patients with higher-risk MDS.